Has Samer Nakhle, MD received payments from drug or device companies?

Yes. Drug and device makers reported $14,474,272 in general payments to Samer Nakhle, MD across 5,331 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samer Nakhle, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samer Nakhle, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samer Nakhle, MD

Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1841281771

Payments from drug & device makers

$14,474,272in general payments, 2019–2025

Across 5,331 payments — averaging $2715.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$7.8M
Amgen$1.5M
Novo Nordisk AS$1.4M
Dexcom, Inc.$1.3M
AbbVie$622K
Sanofi US Services Inc.$544K
plus $1.3M from 54 others

$193,666in research payments, 2019–2025

Across 43 payments — averaging $4503.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$190K
Sanofi US Services Inc.$2K
Sanofi-aventis U.S. LLC$1K
AbbVie$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	178	$7,817,718
Amgen(2 entities)	91	$1,471,117
Novo Nordisk AS	3,313	$1,404,460
Dexcom, Inc.	96	$1,296,425
AbbVie(2 entities)	120	$621,802
Sanofi US Services Inc.	200	$544,202
Lilly USA, LLC	544	$320,760
Pfizer	22	$256,388
CSL Behring	78	$109,096
Novo Nordisk	189	$103,704
Bayer	42	$76,775
Ascendis Pharma Endocrinology Inc	28	$75,337
Globus Medical	5	$48,512
Nevro Corp.	10	$43,287
Ionis Pharmaceuticals, Inc.	12	$40,578
Takeda Pharmaceuticals U.S.A., Inc.	30	$37,160
F. Hoffmann-la Roche AG	14	$36,100
AstraZeneca(2 entities)	26	$32,729
Lexicon Pharmaceuticals, Inc.	2	$23,941
Roche Diagnostics Operations, Inc.	29	$23,847
Boehringer Ingelheim	23	$21,685
Shire North American Group Inc	13	$18,370
Sanofi-aventis U.S. LLC	45	$14,278
Abbott	71	$9,193
Kowa Research Institute, Inc.	3	$8,056
Shionogi Inc	2	$7,732
Genentech, Inc.	2	$7,200
Boehringer Ingelheim International GmbH	2	$442
Mannkind Corporation	19	$321
Kyowa Kirin, Inc.	8	$311
Insulet Corporation	6	$296
Chiesi USA, Inc.	5	$267
Corcept Therapeutics	8	$240
Xeris Pharmaceuticals, Inc.	12	$208
Amarin Pharma, Inc.	4	$178
IBSA Pharma Inc.	8	$148
Medtronic(2 entities)	4	$139
Antares Pharma, Inc.	9	$137
Recordati_rare_diseases_inc.	5	$131
Lifescan, Inc.	7	$129
Radius Health, Inc.	5	$84
Neurocrine Biosciences, Inc.	3	$80
Johnson & Johnson	4	$65
BD	1	$60
Amryt Pharma Holdings Ltd	3	$59
Madrigal Pharmaceuticals	2	$58
Ascensia Diabetes Care US Inc.	3	$52
Soleno Therapeutics, Inc.	2	$48
Amneal Pharmaceuticals LLC	3	$40
Endo Pharmaceuticals Inc.	2	$32
Esperion Therapeutics, Inc.	2	$30
Boston Scientific	2	$28
Exelixis Inc.	1	$25
Embecta Corp.	1	$22
Nestle Healthcare Nutrition Inc.	1	$21
Eisai Inc.	1	$21
Novartis	1	$20
Sequel Med Tech, LLC	1	$20
Zealand Pharma US, Inc.	1	$19
Amphastar Pharmaceuticals, Inc.	1	$19

How this compares

$14,474,272 in reported general payments places this provider in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Medicare billing

Part B allowed, 2024

$233,270

Medicare patients

1,035

Services billed

2,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Las Vegas

Betsy PalalLas Vegas$6.8M
Chakravarthy KannanLas Vegas$144K
Michael UzmannLas Vegas$77K
Molouk RahnemaLas Vegas$73K
Nicholas VernettiLas Vegas$62K
Firhaad IsmailLas Vegas$47K
Bijan AhrariLas Vegas$47K
Freddie ToffelLas Vegas$33K
Mary Ann MartinLas Vegas$16K
Serena KlughLas Vegas$14K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →